{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"202"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Peripheral blood"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.17","value":"317"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Bone marrow"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"This is the summary of cellular kinetic concentrations for tisagenlecleucel (CTL019) transgene levels in peripheral blood and bone marrow following infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants in the Cellular kinetic set (CKAS) with an available value for the outcome measure. The CKAS consisted of patients in the Efficacy analysis set who provided an evaluable cellular kinetic profile (at least 1 cellular kinetic parameter).","reportingStatus":"POSTED","timeFrame":"Month 60 (peripheral blood), Month 6 (bone marrow)","title":"Tisagenlecleucel Transgene Concentration Levels as Measured by Quantitative Polymerase Chain Reaction (qPCR) Method, by Clinical Response Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"copies/ug DNA"}